| DRUG WATCH |
|
| Year : 2013 | Volume
: 45
| Issue : 6 | Page : 634-635 |
A rare case of imatinib-induced erythroderma
Rajesh Verma, Biju Vasudevan, Vijendran Pragasam, Shekhar Neema
Department of Dermatology, Command Hospital, Pune, Maharashtra, India
Correspondence Address:
Biju Vasudevan
Department of Dermatology, Command Hospital, Pune, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.121386
Imatinib, a specific tyrosine kinase inhibitor is a newer anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is generally well tolerated with few side effects. Most commonly reported adverse events are maculopapular eruptions and periorbital edema. Severe adverse reactions are seen in 5% of patients. Exfoliative dermatitis has been very rarely reported with this drug. We report a case of a 52-year-old male who initially presented with a maculopapular rash and developed erythroderma on continuation of the drug.
[FULL TEXT] [PDF]*
|
